The global pandemic of Covid-19 has challenged health-care systems worldwide. Screening of symptomatic and asymptomatic carriers to contain the spread of the disease to vulnerable individuals who suffer severe and life threatening symptoms is vital. To control the spread of Covid-19, we need to identify Covid-19 infected individuals as well as asymptomatic carriers. Screening relies on sensitive and accurate detection of the SARS-CoV-2 viral RNA, which is responsible for Covid-19. RT-PCR, the conventional lab-scale method of viral RNA detection, is time consuming, requires specialized training and advanced equipment. With CardiAI’s CoviLamp™ (SARS-CoV-2 Screening Assay Kit), the viral RNA can be detected in as less than 30 minutes depending upon the viral load criteria of individual lab with less specialized equipment and minimal training. The CoviLamp™ assay kit uses reverse transcription loop-mediated isothermal amplification (RT-LAMP), which amplifies SARS-CoV-2 RNA faster than traditional RT-PCR with a colorimetric endpoint readout. Detection of viral RNA can be performed by a plate reader capable of measuring absorbance at 430 nm and 560 nm.
CoviLamp™ overcomes RT-PCR challenges of:
Expensive equipment & specialized personnel.
Global Reagent supply chain shortages.
LAMP compared to
LAMP occurs in isothermal conditions, allowing the test to be performed with more versatile laboratory equipment (heat blocks, water baths, programmable ovens etc.
Clinical-scale method produced by CardiAI Inc. is designed for use with a plate reader, the kit can also be reduced to a small scale reactions observed by eye.
Being isothermal also permits continuous generation of concatemers of nucleic acid coupled with pH change leading to colour change from pink to yellow.